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mineralization lag time, (that is, the rate at which osteoid miner-22-Oxacalcitriol suppresses secondary hyperparathyroidism
alizes) in both Nx and Sham dogs.without inducing low bone turnover in dogs with renal failure.
Conclusions. These results indicate that even though OCTBackground. Calcitriol therapy suppresses serum levels of
does not completely prevent the occurrence of hypercalcemiaparathyroid hormone (PTH) in patients with renal failure but
in experimental dogs with renal insufficiency, it may be of usehas several drawbacks, including hypercalcemia and/or marked
in the management of secondary hyperparathyroidism becausesuppression of bone turnover, which may lead to adynamic
it does not induce low bone turnover and, therefore, does notbone disease. A new vitamin D analogue, 22-oxacalcitriol
increase the risk of adynamic bone disease.(OCT), has been shown to have promising characteristics. This
study was undertaken to determine the effects of OCT on
serum PTH levels and bone turnover in states of normal or
impaired renal function. The administration of calcitriol has become a standard
Methods. Sixty dogs were either nephrectomized (Nx, N 5 therapeutic measure in the management of secondary
38) or sham-operated (Sham, N 5 22). The animals received
hyperparathyroidism in patients with end-stage renalsupplemental phosphate to enhance PTH secretion. Fourteen
failure. Although daily oral calcitriol therapy suppressesweeks after the start of phosphate supplementation, half of
serum levels of parathyroid hormone (PTH) [1–5], it hasthe Nx and Sham dogs received doses of OCT (three times
per week); the other half were given vehicle for 60 weeks. several drawbacks, including hypercalcemia, particularly
Thereafter, the treatment modalities for a subset of animals when calcium salts are used for phosphate binding [6, 7]
were crossed over for an additional eight months. Biochemical and/or marked suppression of bone turnover, which may
and hormonal indices of calcium and bone metabolism were lead to adynamic bone disease [8, 9].measured throughout the study, and bone biopsies were done
To overcome these limitations, other approaches areat baseline, 60 weeks after OCT or vehicle treatment, and at
being used, such as adjustment in dialysate calcium con-the end of the crossover period.
Results. In Nx dogs, OCT significantly decreased serum PTH tent [10] or intermittent intravenous or oral administra-
levels soon after the induction of renal insufficiency. In long- tion of the sterol [11, 12]. However, hypercalcemia, hy-
standing secondary hyperparathyroidism, OCT (0.03 mg/kg) perphosphatemia, and adynamic bone disease still occur
stabilized serum PTH levels during the first months. Serum [13–16]. Therefore, alternatives have been proposed,PTH levels rose thereafter, but the rise was less pronounced
such as early treatment to prevent the development ofcompared with baseline than the rise seen in Nx control. These
nodular parathyroid hyperplasia or treatment with vita-effects were accompanied by episodes of hypercalcemia and
hyperphosphatemia. In animals with normal renal function, min D analogues of less calcemic activity.
OCT induced a transient decrease in serum PTH levels at a Among the many vitamin D analogues that have
dose of 0.1 mg/kg, which was not sustained with lowering of been generated, 1,25-(OH)2-22-oxa-D3, or 22-oxacalcitriolthe doses. In Nx dogs, OCT reversed abnormal bone formation, (OCT), which differs from calcitriol by substitution ofsuch as woven osteoid and fibrosis, but did not significantly
an oxygen atom from the methylene group at carbon 22alter the level of bone turnover. In addition, OCT improved
[17], has promising characteristics for nephrologists. 22-
Oxacalcitriol suppresses PTH mRNA expression in vitro
[18, 19] and in vivo [18–20]. Short-term administrationKey words: parathyroid hormone, calcitriol, hypercalcemia, hyper-
phosphatemia, adynamic bone disease. of OCT results in decreased serum PTH levels in normal
rats [21] and in rats and dogs with renal failure [20,Received for publication October 16, 1997
22–26]. Most important is that OCT treatment was shownand in revised form September 30, 1998
Accepted for publication September 30, 1998 to induce no or fewer calcemic and phosphatemic effects
than calcitriol [18, 23–34]. 1999 by the International Society of Nephrology
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The effects of OCT on bone, however, are not well tions, measurements of creatinine clearances, and open
defined. In a manner similar to calcitriol, OCT has been iliac crest bone biopsies. In order to complete the experi-
shown to bind to vitamin D receptor in osteoblast-like ment in at least 10 dogs per groups, the animals were
cells [35, 36], to promote alkaline phosphatase, osteonec- randomly allocated to undergo either 5/6 and one ne-
tin, and osteopontin production [35–38], and to stimulate phrectomy (Nx, N 5 38) or sham operation (Sham,
enchondral and intramembranous ossification [39]. How- N 5 22). After surgery, dogs were followed for a period
ever, OCT has also been shown in vitro to inhibit DNA of approximately one month to allow renal function to
synthesis and alkaline phosphatase activity in osteoblas- stabilize. At that time, creatinine clearances were re-
tic MC3T3-E1 cells [40] and collagen synthesis in organ peated, and phosphate supplementation was given (see
culture [41]. In vitro studies on the bone-resorbing activ- below) to stimulate PTH secretion further and was con-
ity of OCT are also controversial [17, 27, 40–42]. It is of tinued throughout the experiment. Fourteen weeks after
note, however, that these data have been obtained in the beginning of phosphate supplementation, Sham dogs
various in vitro models and that these studies were con- were randomly allocated to receive either intravenous
ducted under different conditions. Only two studies re- injections of OCT or vehicle three times a week for 60
port the effects of short-term OCT administration on weeks. Nx dogs were matched based on their creatinine
bone histology and show either no effect in normal rats clearances. At the end of the treatment period, the dogs
[21] or improvement in mineralization in vitamin D- underwent blood drawings, urine collections, determina-
deficient mice [33]. tions of creatinine clearances, and a second iliac crest
The long-term in vivo effects of OCT administration biopsy.
on calcium metabolism and bone turnover are not Phase 2 was started one to two weeks after the second
known. This study was undertaken to determine these bone biopsies. During these one to two weeks, dogs were
effects in states of both normal and impaired renal func- not dosed with OCT or vehicle but continued to receive
tion in an animal model with remodeling characteristics phosphate supplementation. Thereafter, animals that
similar to the human skeleton. were treated before with vehicle or OCT received OCT
(at the same maintenance dose) or vehicle for a duration
of eight months. At the end of phase 2, the dogs under-METHODS
went blood and urine collections and a third iliac crestExperimental design
biopsy. The animals were then sacrificed, and necropsies
The experiment was designed as a prospective 2 3 2
were performed.factorial study to evaluate the effect of (a) the adminis-
tration of OCT versus vehicle and (b) renal insufficiency Monitoring of the experiment
versus normal renal function on serum levels of calcio-
Physical well-being of the dogs was observed and re-tropic indices and bone histology in beagle dogs. The
corded on a daily basis. Body weight was measured regu-study was conducted in two phases. Phase 1 was carried
larly. Serum levels of creatinine, calcium, phosphorus,out to determine the prophylactic value of OCT in the
and PTH were measured at least every month. Serumdevelopment of secondary hyperparathyroidism and its
levels of osteocalcin and calcitriol levels were determinedskeletal consequences in animals with renal failure.
at baseline, 15, 30, and 50 weeks after administration ofPhase 2 was conducted after a crossover of phase 1 treat-
OCT or vehicle and at the end of phase 1 and 16 andment modalities to investigate whether OCT at the same
32 weeks after the beginning of the crossover study.dose can be effective in treating established secondary
Phosphate supplementation was started at a dose ofhyperparathyroidism and to determine the effects of dis-
1.62 g of liquid monobasic sodium and dibasic sodiumcontinuation of OCT on calcium and bone metabolism.
phosphate (10 ml of Fleet Phosphosoda; C.B. Fleet Co.,
Experimental animals Inc., Lynchburg, VA, USA) mixed with food. Doses of
phosphate were then progressively increased as toleratedSixty full-grown, female, five- to six-year-old, colony-
(absence of diarrhea). When serum phosphorus reachedraised beagle dogs were purchased from a USDA-licensed
5.0 mg/dl, phosphate supplementation was withheld untildealer (Hazleton Research Products, Inc., Kalamazoo,
serum phosphorus levels were below 4.0 mg/dl. Phos-MI, USA). After arrival, the dogs were quarantined for
phate supplementation was then resumed. When serumtwo weeks and acclimated to their new environment.
phosphorus levels were above 5.0 mg/dl in the presenceThey were housed in runs that allowed ample exercise
of deterioration of renal function (serum creatinine moreand regular exposure to sunlight. Physical condition and
than 3.5 mg/dl), phosphate was withheld, and the animalsactivity levels of the dogs were monitored daily.
were fed 1.5 cans of a special diet (discussed later here),
Protocol until serum phosphorus fell below 4.0 mg/dl.
The administration of OCT (Chugai PharmaceuticalAt the beginning of phase 1, the animals underwent
baseline studies, including blood drawings, urine collec- Co., Ltd., Tokyo, Japan) or vehicle (phosphate-buffered
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saline containing 0.2% ethanol and 0.01% Tween 20) the Kodak Ektachem DT 60 Analyzer (Eastman Kodak,
Rochester, NY, USA).was started at a dose of 0.01 mg/kg body wt. The dose
was then progressively increased to reach the mainte- Serum PTH levels were determined in duplicate using
the two-sites immunoradiometric assay for intact PTHnance dose, that is, the highest dose that did not induce
hypercalcemia (serum calcium levels above 11 mg/dl) in [45] through the use of the Allegroe Intact PTH assay
kit from the Nichols Institute (San Juan Capistrano, CA,Nx dogs. When the maintenance dose was determined,
both Nx and Sham dogs allocated to receive OCT re- USA). This assay has been validated in beagle dogs [46].
The intra-assay coefficients of variation of the 35 assaysceived the same maintenance dose. During the experi-
ment, serum calcium was closely monitored, and when used for the experiment ranged from 0.1 to 10.5% (me-
dian 1.5%). The interassay coefficients of variation forvalues were between 11.0 and 11.4 mg/dl, the dose of
OCT was reduced by half until serum calcium decreased. the two sets of standards used for the experiment were
2.7 and 7.6%.When serum calcium was above 11.5 mg/dl, OCT admin-
istration was discontinued until normalization of serum Serum osteocalcin concentrations were measured in
duplicate using our polyclonal antiserum-based radioim-calcium. In both cases, increments in doses were subse-
quently attempted with careful monitoring of serum cal- munoassay for dog osteocalcin [47]. The detection limit
of the assay was 0.1 ng; the intra-assay coefficients ofcium levels.
variation of the seven assays varied from 3.2 to 10.3%
Surgical procedures (median 4.8%). The interassay coefficients of variation
were 5.6 to 8.4%, respectively.Five/six and one nephrectomy was performed ac-
cording to the method of Platt, Roscoe and Smith under Measurements of serum levels of calcitriol were done
using the 1,25(OH)2D assay kit (Nichols Institute) [48].general anesthesia (isofluorane, 1 to 1.5%) [43]. During
the first operation, all but one tertiary branch of the The intra-assay variation of the 13 assays was less than
2.8%, and the interassay variation was 4.0%.renal artery were ligated. Two weeks later, contralateral
nephrectomy was performed. Sham operations were also
Mineralized bone histology andperformed in two steps under general anesthesia, and
bone histomorphometrythe kidneys were examined for normality.
Bone biopsies of the iliac bone were done through a Iliac bone samples were fixed in absolute ethanol, de-
hydrated, and embedded in methylmethacrylate as pre-lateral flank incision using general anesthesia (isofluor-
ane). They were performed with a Stryker bone saw viously described [49]. Serial sections of 3 and 7 mm
thickness were cut with a Microm microtome, modelequipped with stainless steel blades. Double labeling of
bone was done in all animals before bone biopsies. To HM360 (Carl Zeiss, Thornwood, NY, USA). Three-
micrometer thick sections were stained with the modifiedallow differentiation of the labels given before each
biopsy, two different bone markers were used in each Goldner Trichrome stain [50]. Seven-micrometer thick,
unstained sections were prepared for phase contrast anddog: tetracycline hydrochloride at a dose of 20 mg/kg
body wt/day and calcein at a dose of 15 mg/kg body wt/ fluorescent light microscopy. Two bone samples were
cut from each iliac bone specimen, processed, and em-day. All bone markers were given for two days, followed
by a labeling-free interval of six to seven days and a bedded, allowing sagittal and medial sectioning. Histo-
morphometry of bone was performed at a standardizedsecond two-day administration of the marker. Biopsies
were done three days after the second label was given. site below the cortices.
Static and dynamic parameters of bone structure, for-Measurements of creatinine clearance were carried
out in anesthetized dogs using exogenous creatinine infu- mation, and resorption were measured using the Os-
teoplan system II (Kontron, Munich, Germany) [51, 52].sion [44].
Histologic features were measured at a magnification of
Diets 3200 (50 optical fields). The histologic sections were
analyzed after completion of the study and withoutDogs were fed a diet providing 9.6% crude protein,
6.6% crude fat, 0.1% fiber, 0.42% calcium, and 0.31% knowledge of animal number or group. All parameters
are in compliance with and were calculated according tophosphorus. The amount of diet varied from 472 to 531
g/day. When renal function deteriorated, animals were the recommendations of the histomorphometry nomen-
clature committee of the American Society of Bone andfed a diet providing lower protein, calcium, and phospho-
rus intake (3.5% crude protein, 6.0% crude fat, 2.0% Mineral Research [53].
crude fiber, 0.25% calcium, and 0.15% phosphorus).
Statistical analysis
Analytical methods Results are expressed as mean 6 sem. All statistical
tests were two sided. An assigned significance level ofConcentrations of serum calcium, phosphorus, and
creatinine and urinary creatinine were determined by 0.05 was used. Normality of distribution was assessed by
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at a dose of 0.1 mg/kg body wt in Nx dogs (Fig. 2).
At that point (week 15 of treatment), OCT doses were
decreased, and the maintenance dose for both Nx and
Sham animals for the rest of the study was 0.03 mg/kg
body wt/injection. However, the cumulative dose of OCT
was significantly higher in Sham than in Nx dogs (Table
1). This was due to significantly fewer OCT withdrawals
in Sham than in Nx dogs (Table 1). Eight Nx dogs were
either treated continuously (N 5 2), or the OCT treat-
ment was interrupted during 15 6 5.4% of the time
during Phase 1 (range 1.7 to 38.3%). Three Nx dogs
could be treated for less than 50% of the time during
phase 1 because of persistent hypercalcemia.
Results, including the originally unmatched three Nx
dogs that were given vehicle during the study, were statis-
tically similar to analyses excluding them; therefore, all
Nx control dogs are presented. Protein and phosphate
Fig. 1. Changes in serum creatinine levels in nephrectomized (Nx) intakes were not different among the experimentalor sham-operated animals (Sham) receiving 22-oxacalcitriol (OCT) or
groups, and body weights did not change during the studyvehicle (Veh) during Phase 1 of the study. Nx 1 OCT ( ); Nx 1 Veh
(h); Sham 1 OCT (d); Sham 1 Veh (s). Surgery (Nx or Sham) was (Table 1). Renal functions were similar in the two Nx
done at time 220 weeks, OCT or Veh treatment started at time 0. groups and were unaltered in the Sham animals (Fig. 1
and Table 1).
Effects of 22-oxacalcitriol on development of
the Lilliefors test, and homogeneity of variance was
secondary hyperparathyroidism in
tested with the Levene test. Adequate transformations
nephrectomized dogs
of the data were done when results did not meet the
In OCT-treated Nx dogs, serum PTH started to fallcharacteristics assumed for analysis of variance [54]. The
shortly after initiation of therapy and stayed stable there-comparability of two or four groups was tested by t-test
after in the 8 out of 11 dogs that were treated moreor one-way analysis of variance with the Bonferroni post
than 50% of the experimental duration, whereas serumhoc test, respectively. Serial changes were analyzed by
calcium levels rose initially but decreased thereafter andtwo-way analysis of variance for repeated measures.
stabilized during the remainder of the study (Fig. 2A).All computations were performed using the SPSS soft-
In these dogs, serum calcium levels were not significantlyware package for Windows release 6.0 (SPSS, Chicago,
different at the end of the study (Fig. 2A) from thoseIL, USA).
of Nx animals given vehicle (Fig. 2C). In the three Nx
dogs treated less than 50% of the time, serum PTH
RESULTS levels decreased initially but rose significantly thereafter,
despite persistently elevated serum calcium (Fig. 2B). AShortly after surgery, a severe loss of kidney function
requiring early euthanasia occurred in six Nx dogs. In progressive increase in serum PTH was also observed in
Nx dogs given vehicle with no change in serum calciumthe remaining Nx dogs, renal function stabilized 10 weeks
after surgery (Fig. 1). The Nx dogs showed a rapid and concentrations (Fig. 2C).
Similar to serum calcium, at week 15, serum phospho-transient increase in serum calcium (Fig. 2) and phospho-
rus (Fig. 3) levels, which subsided before initiation of rus increased significantly in Nx dogs given OCT (Fig.
3). Thereafter, serum phosphorus stabilized in the Nxtreatment. Serum PTH levels rose rapidly in Nx dogs
(Fig. 2). In Nx dogs, creatinine clearances could be pre- dogs treated with OCT, whereas a progressive increase in
serum phosphorus occurred in Nx dogs receiving vehiclecisely matched in 12 pairs of dogs; the 8 unmatched dogs
were allocated to receive vehicle. During the experiment, (Fig. 3). Serum phosphorus levels were slightly lower in
Nx dogs that could be treated regularly with OCT thanfive of the unmatched Nx dogs given vehicle, and one
Nx dog treated with OCT died from advanced renal in the ones that could not; however, this difference was
not significant. At the end of the study, serum phospho-failure. In addition, a Sham dog receiving vehicle was
sacrificed because of general malaise and lethargy. Au- rus levels were equally elevated in the Nx animals (with
and without OCT) and were significantly higher thantopsy revealed hepatorenal amyloidosis.
22-Oxacalcitriol was started at a dose of 0.01 mg/kg levels in the Sham dogs (Fig. 3).
OCT treatment in Nx dogs induced a decrease in se-body wt and progressively increased thereafter. An in-
crease in serum calcium levels above 11 mg/dl occurred rum calcitriol concentrations (Table 2). Serum osteocal-
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Fig. 2. Changes in serum parathyroid hormone (d) and serum calcium (s) levels in nephrectomized (Nx) animals receiving 22-oxacalcitriol (OCT)
for more than 50% of the time (Nx 1 OCT . 50%, less than 50% of the time (Nx 1 OCT , 50%), or vehicle (Veh) during phase 1 of the study.
Surgery (Nx or Sham) was done at time 220 weeks. OCT or Veh treatment started at time 0.
resorption; this reached statistical significance only for
osteoclast number (Table 4). However, these parameters
were still significantly higher than those in Sham animals
(Table 3). 22-Oxacalcitriol did not affect bone formation
or bone turnover (Table 3). This was especially evident
in Nx dogs treated with OCT for more than 50% of the
time. These animals had serum PTH levels significantly
lower than dogs receiving vehicle or OCT less than 50%
of the time (Fig. 2) with similar activation frequency
(4.71 6 0.49 vs. 4.59 6 0.45 or 5.19 6 1.31 per year,
respectively).
In addition to the beneficial effects of OCT in pre-
venting abnormal bone structure (woven osteoid and
fibrosis) and preserving bone turnover, OCT treatment
in Nx dogs resulted in less accumulation of osteoid and
similar mineralizing surface/bone surface compared with
vehicle treatment. This indicates faster mineralization ofFig. 3. Changes in serum phosphorus levels in nephrectomized (Nx)
or sham-operated animals (Sham) receiving 22-oxacalcitriol (OCT) or osteoid (shorter mineralization lag time) in OCT-treated
vehicle (Veh) during phase 1 of the study. Symbols are: ( ) Nx 1 Nx dogs (Table 3).OCT; (h) Nx 1 Veh; (d) Sham 1 OCT; (s) Sham 1 Veh. Surgery
(Nx or Sham) was done at time 220 weeks, OCT or Veh treatment
started at time 0. Effect of 22-oxacalcitriol on established secondary
hyperparathyroidism in nephrectomized dogs
Renal function and serum calcium and phosphorus
levels were similar in the two groups of Nx dogs thatcin levels increased significantly in Nx dogs and were
were crossed over at the onset of phase 2 (Table 5).not affected by OCT treatment (Table 2).
OCT treatment was started at the maintenance doseResults of bone histomorphometry are shown in Table
given in phase 1 (0.03 mg/kg body wt three times per3. Nx dogs receiving vehicle showed changes compatible
week) in all dogs assigned to receive the vitamin D ana-with hyperparathyroid renal bone disease, including a
logue, except for one Nx dog, which was given half ofsignificant increase in bone turnover with high bone for-
the OCT dose because serum calcium was 11.4 mg/dl atmation, woven osteoid formation, peritrabecular fibrosis,
the start of phase 2. Of the 27 animals that entered theand high bone resorption (Table 3). 22-Oxacalcitriol at-
crossover study, two Nx dogs died from advanced renaltenuated significantly the formation of abnormal woven
failure (one dog given vehicle, one dog receiving OCT).osteoid, accumulation of lamellar osteoid, and appear-
OCT treatment had to be discontinued for extendedance of peritrabecular fibrosis (Table 3). 22-Oxacalcitriol
treatment also tended to mitigate the increase in bone periods of time in two dogs; the other six animals re-
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Table 1. Body weights, protein and phosphate intakes, doses of 22-oxacalcitriol (OCT), and time off therapy in nephrectomized (Nx) or
sham-operated (Sham) dogs receiving OCT or vehicle (Veh) during Phase 1
NX 1 Veh NX 1 OCT Sham 1 Veh Sham 1 OCT
(N 5 15) (N 5 11) (N 5 10) (N 5 11)
Body weight kg
Baseline 10.760.44 10.660.28 10.460.56 10.660.47
End of Phase 1 9.6 60.66 9.660.47 10.060.77 10.360.67
Protein intake g/week 240.762.9 243.062.9 246.860.5 247.060.6
Supplemental phosphate g/week 6.760.8 7.660.8 9.360.5 9.260.5
Total phosphate g/week 17.860.8 18.860.8 20.660.5 20.560.4
Cumulative dose of OCT lg/kg body wt NA 5.7660.57 NA 7.97 60.11a
Time off OCT % NA 24.4167.61 NA 1.38 60.002a
Results are given as mean 6 sem.
a Significantly different from Nx dogs given OCT, P , 0.01, t-test
Table 2. Serum biochemical results in nephrectomized (Nx) or sham-operated (Sham) dogs receiving 22-oxacalcitriol (OCT)
or vehicle (Veh) during Phase 1
NX 1 Veh NX 1 OCT Sham 1 Veh Sham 1 OCT
(N 5 15) (N 5 11) (N 5 10) (N 5 11)
Creatinine clearance ml/min
Baseline 29.261.2 26.1 60.9 28.1 61.8 30.2 61.5
Before treatment 10.061.0 12.0 61.1 20.7 61.3 34.8 61.7
End of Phase 1 8.6 61.5ab 10.761.8ab 32.661.9 38.1 62.1
Serum calcitriol levels pg/ml
Baseline 35.862.9 32.5 63.3 33.8 61.4 30.8 63.3
End of Phase 1 32.4 62.6 23.0 66.0c 25.262.6 15.2 61.8c
Osteocalcin ng/ml
Baseline 8.660.9 8.3 61.0 9.0 61.2 6.4 60.9
End of Phase 1 91 620.6ab 121650.1ab 11.261.3 12.9 61.3
Results are given as mean 6 sem.
a Significant effect of nephrectomy, P , 0.01, two-way analysis of variance for repeated measures
b Significantly different from Sham animals, P , 0.01, one-way analysis of variance, Bonferroni post-hoc test
c Significant effect of OCT, P , 0.01, two-way analysis of variance for repeated measures
ceived OCT during 74.2 6 9.6% of the duration of the OCT treatment stabilized bone turnover to values simi-
lar to those found in Sham animals (Table 6). The mostcrossover study.
At the onset of phase 2, serum PTH levels were sig- striking effect of OCT in Nx dogs was the shortening in
nificantly higher in Nx dogs that had received vehicle mineralization lag time, which was prolonged at the start
during phase 1 than in Nx dogs that had received OCT of phase 2 (Table 6).
(Fig. 4). After discontinuation of OCT, Nx dogs treated
Effects of 22-oxacalcitriol on dogs with normal renalwith vehicle nearly quadrupled their serum PTH levels
function and bone turnover(Fig. 4), whereas Nx dogs given OCT during phase 2
had stable serum PTH levels until month 4; thereafter, In Sham dogs, the administration of OCT was well
tolerated, and treatment had to be discontinued in onlythey showed a significant increase (Fig. 4) accompanied
by a further rise in serum osteocalcin levels but without four dogs for a short period of time during phase 1
(Table 1) and not at all after crossover. Serum PTHchanges in serum calcium or phosphorus levels (Table
5). The decrease in serum calcitriol levels observed in Nx levels decreased slightly, although significantly, shortly
after the administration of the highest dose of OCTdogs given OCT during phase 1 was reversed early after
discontinuation of the drug during phase 2 (Table 5). (week 15) and were lower than those of vehicle-treated
Sham dogs at that time point (Table 7). With loweringSwitching of treatment modalities in Nx dogs resulted
in opposite changes in osteoid indices; that is, OCT in- of OCT doses, these differences were no longer observed
(Table 7). Serum PTH levels did not change during theduced a decrease in lamellar and woven osteoid, but
these parameters increased, at various degrees, in Nx crossover study (Fig. 4). There were no effects of OCT
on mean serum calcium, phosphorus, osteocalcin, andanimals given vehicle (Table 6). Parameters of bone re-
sorption in Nx dogs were not significantly affected by renal function during either phase of the study (Figs. 1
and 3; Tables 2, 5 and 7). Serum calcitriol levels de-crossover (Table 6). Bone turnover (activation fre-
quency) increased in Nx dogs given vehicle, whereas creased in Sham dogs given OCT and reverted to normal
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Table 3. Histomorphometric parameters of bone structure and formation in nephrectomized (nx) or sham-operated (Sham) dogs receiving
22-oxacalcitriol (OCT) or vehicle (Veh) during Phase 1
NX 1 Veh NX 1 OCT Sham 1 Veh Sham 1 OCT
(N 5 15) (N 5 11) (N 5 10) (N 5 11)
Parameters of bone structure
Bone volume/tissue volume %
Baseline 21.7860.91 22.5060.97 21.9361.42 22.9761.27
End of Phase 1 26.42 61.37 25.8361.47 23.3961.26 24.1661.39
Trabecular thickness lm
Baseline 75.0761.92 73.1661.78 75.5563.92 75.9062.40
End of Phase 1 79.95 63.60 73.1661.78 76.6862.95 76.2463.62
Parameters of bone formation
Osteoid volume/bone volume %
Baseline 2.6160.23 2.5360.22 3.0160.16 2.5660.24
End of Phase 1 9.61 60.65a 6.1660.50ab 2.8560.10 3.0760.27
Lamellar osteoid surface/bone surface %
Baseline 18.8361.13 17.5261.46 20.1661.19 19.2060.98
End of Phase 1 47.40 62.63a 9.3462.10ab 21.6161.58 20.3961.33
Woven osteoid surface/bone surface %
Baseline 0 0 0 0
End of Phase 1 2.01 60.43a 0.4760.13ab 0 0
Osteoid thickness lm
Baseline 5.0860.16 5.3260.28 5.6360.26 4.9760.25
End of Phase 1 7.76 60.43a 6.1360.27ab 5.1660.19 5.6260.17
Osteoblast number/bone length N/100 mm
Baseline 280616.8 262629.0 272614.6 300622.7
End of Phase 1 852 696.9a 703654.7a 320642.4 315634.9
Fibrosis surface/bone surface %
Baseline 0 0 0 0
End of Phase 1 1.48 60.47a 0.4260.30ab 0 0
Mineral apposition rate lm/day
Baseline 0.9460.05 0.8860.05 0.9260.05 0.8360.03
End of Phase 1 1.20 60.08a 1.1860.08a 0.9460.05 0.9060.07
Mineralizing surface/bone surface %
Baseline 14.4560.86 13.0162.06 17.4661.08 11.8162.02
End of Phase 1 35.55 62.22a 37.2862.18a 24.2362.33 22.2461.88
Bone formation rate/bone surface mm3/cm2/year
Baseline 5.0260.46 4.4060.80 6.0060.66 3.5960.62
End of Phase 1 15.48 61.42a 16.1061.48a 8.2060.81 7.2360.81
Activation frequency year21
Baseline 1.4060.13 1.2860.24 1.7160.19 1.0560.19
End of Phase 1 4.59 60.45a 4.7560.51a 2.3860.24 2.1460.22
Mineralization lag time days
Baseline 9.0460.89 11.9362.98 8.8760.78 14.5162.14
End of Phase 1 12.68 61.54 7.2261.11 6.3060.62c 7.6260.86c
Results are given as mean 6 sem.
a Significant effect of nephrectomy, P , 0.01, two-way analysis of variance for repeated measures
b Significant effect of OCT in nephrectomized dogs, P , 0.01, analysis of variance
c Significant effect of OCT, P , 0.01, two-way analysis of variance for repeated measures
Table 4. Histomorphometric parameters of bone erosion and bone dynamics in nephrectomized (Nx) or sham-operated (Sham) dogs
receiving 22-oxacalcitriol (OCT) or vehicle (Veh) during Phase 1
NX 1 Veh NX 1 OCT Sham 1 Veh Sham 1 OCT
(N 5 15) (N 5 11) (N 5 10) (N 5 11)
Erosion surface/bone surface %
Baseline 3.1760.19 3.2660.24 3.1960.20 3.1660.19
End of Phase 1 11.16 60.62a 8.8661.08a 3.2560.226 3.5260.26
Erosion depth lm
Baseline 5.5160.19 5.0760.34 5.9360.33 5.6060.30
End of Phase 1 8.77 60.63a 7.6560.46a 5.5960.28 5.8160.44
Osteoclast number/bone length N/100 mm
Baseline 46.4362.55 46.7263.18 45.6662.99 45.0363.40
End of Phase 1 149.58 66.61a 116.98614.31ab 48.1663.47 52.3763.74
Results are given as mean 6 sem.
a Significant effect of nephrectomy, P , 0.01, two-way analysis of variance for repeated measures
b Significant effect of OCT in nephrectomized dogs, P , 0.01, analysis of variance
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Table 5. Body weight and serum biochemistry in nephrectomized (Nx) or sham-operated (Sham) dogs receiving 22-oxacalcitriol (OCT)
or vehicle (Veh) at the end of Phase 1 and after crossover (→)
Nx 1 Veh → Oct Nx 1 Oct → Veh Sham 1 Veh → Oct Sham 1 Oct → Veh
(N 5 8) (N 5 4) (N 5 6) (N 5 7)
Body weight kg
Before 11.0960.99 9.65 60.56 9.75 61.16 10.2360.90
After 10.4461.02 10.30 60.49 10.52 60.96 11.0760.80
Creatinine clearance ml/min
Before 7.2761.21a 8.5062.56a 33.3063.26 39.9662.34
After 7.9962.76c 7.3061.59c 27.9361.61 33.3460.79
Serum calcium mg/dl
Before 10.5960.25 11.00 60.25 10.18 60.16 10.0960.17
After 10.8860.28 10.05 60.54 9.95 60.17 9.9760.16
Serum phosphorus mg/dl
Before 4.4860.42a 5.6360.52a 2.9760.10 2.8760.15
After 6.5961.13a 6.4561.01a 2.1260.11 2.3760.14
Serum calcitriol pg/ml
Before 35.9062.30 19.13 63.55c 28.2561.68 16.6762.22c
After 21.461.76 29.4562.83b 26.7362.78 34.7963.94b
Serum osteocalcin ng/ml
Before 109.3624.6a 95.7633.0a 12.261.6 13.561.7
After 245670.1ab 137648.1a 12.9761.22 13.0361.66
Results are given as means 6 sem.
a Significantly different from Sham animals, P , 0.01, one-way analysis of variance, Bonferroni post-hoc test
b Significant increase from baseline, P , 0.05, analysis of variance for repeated measures
c Significantly different from animals receiving Veh → OCT, P , 0.01, one-way analysis of variance, Bonferroni post-hoc test
studies conducted in nephrectomized rats and dogs [20,
22–26]. In addition, in established hyperparathyroidism,
OCT given at a constant dose of 0.03 mg/kg three times
per week stabilized serum PTH levels for four months.
The increase observed thereafter was not as pronounced
(compared with baseline) as the one seen in control Nx
animals given vehicle. In pronounced hyperparathyroid-
ism, that is, when serum PTH levels are approximately
400 pg/ml, a higher dose of OCT is needed to control
PTH levels in experimental dogs. This is in agreement
with a preliminary study in hemodialyzed patients treat-
ed for 12 weeks with OCT at doses ranging from 5.5 to
11 mg three times a week [55]. Long-term studies in
humans are needed to evaluate the safety and efficacy of
OCT administration in patients on chronic maintenance
dialysis.
Fig. 4. Changes in serum parathyroid hormone levels in nephrecto- The suppressive effects of OCT on serum PTH levelsmized (Nx) or sham-operated animals (Sham) receiving 22-oxacalcitriol
in Nx animals were accompanied by episodes of hyper-(OCT) or vehicle (Veh) after crossover. Symbols are: ( ) Nx 1 OCT;
(h) Nx 1 Veh; (d) Sham 1 OCT; (s) Sham 1 Veh. calcemia and hyperphosphatemia, despite the reduction
in circulating calcitriol. Decreased serum calcitriol levels
with OCT have been described before [26, 56–58]. Epi-
sodes of hypercalcemia have also been observed in short-after discontinuation of the metabolite (Tables 2 and 5).
term studies in rats with renal failure [23] and hemodia-At the maintenance dose employed, OCT induced a
lyzed patients [55] but were not found in other studiesmoderate but significant shortening of mineralization lag
in rats and dogs with renal failure [20, 22, 24, 25]. Differ-time, without affecting other histologic parameters (Ta-
ences in OCT doses cannot explain these discrepancies.ble 6).
Also, even though higher binding of OCT to vitamin D-
binding protein has been found in dogs than in rats and
DISCUSSION humans [59], resulting in prolonged half-life of OCT in
the canine model, it is unlikely that species differencesThe study shows that the administration of OCT can
could play a role because hypercalcemia was observedprevent the progressive rise in serum PTH levels in renal
failure and confirms the results of previous short-term in rats, dogs, and humans. The duration of OCT adminis-
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Table 6. Parameters of bone formation in 25 dogs sham-operated (Sham) or nephrectomized (Nx) treated with 22-oxacalcitriol (OCT) or
vehicle (Veh) at the end of Phase 1 and after crossover (→)
Nx 1 Veh → OCT Nx 1 OCT → Veh Sham 1 Veh → OCT Sham 1 OCT → Veh
(N 5 8) (N 5 4) (N 5 6) (N 5 7)
Bone volume/tissue volume %
Before 29.8560.97 26.3663.18 25.4161.02 26.13 61.75
After 25.3560.75 26.3362.46 24.2761.01 25.48 61.06
Osteoid volume/bone volume %
Before 10.7060.81a 5.3260.44b 2.8360.13 2.95 60.28
After 7.0260.94c 8.8461.87bc 4.0860.59 4.30 60.66
Lamellar osteoid surface/bone surface %
Before 49.8462.36a 37.9864.01b 21.3662.12 20.64 61.76
After 48.2664.91 53.5365.91d 32.4663.75 32.53 64.09
Woven osteoid surface/bone surface %
Before 2.7860.63a 0.2860.18 0 0
After 0.3160.16 0.6160.27 0 0
Osteoid thickness lm
Before 8.7960.52 5.8560.45 5.3260.29 5.69 60.17
After 5.9260.20c 6.3060.90c 5.0860.24 5.35 60.31
Osteoblast number/bone length N/100 mm
Before 10786119.2a 727660.1 352668.5 329 653.0
After 7376122 12056206bc 549699.6 753 6103
Erosion surface/bone surface %
Before 10.8360.85a 8.7460.56a 3.2860.34 3.84 60.27
After 8.7760.71bc 5.5161.33c 2.5460.38 3.05 60.51
Osteoclast number/bone length N/100 mm
Before 147.7464.33a 96.7161.98b 53.9464.28 58.66 63.71
After 114.67614.07a 76.48618.74 37.6065.61 46.58 67.01
Fibrosis surface/bone surface %
Before 1.4760.79 0.1360.13 0 0
After 0.3160.24 0.0560.05 0 0
Activation frequency year21
Before 4.6660.73b 4.3561.19b 2.6060.33 2.30 60.34
After 5.5660.67 7.0560.93a 4.7460.87 5.62 61.03a
Mineralization lag time days
Before 14.2362.22a 6.2760.72 6.0160.84 7.29 61.02
After 6.3061.25c 4.7560.98 7.5464.06 4.21 60.66
Results are given as means 6 sem.
a Different from all other groups, P , 0.01, one-way analysis of variance, Bonferroni post-hoc test
b Different from Sham groups, P , 0.01, one-way analysis of variance, Bonferroni post-hoc test
c Significant effects of treatment modalities in Nx dogs, P , 0.01, analysis of variance for repeated measures
d Significant increase from eand of Phase 1, P , 0.05
tration may have contributed because the studies without an in vivo dose-response study of the effect of OCT on
frank hypercalcemia consisted of either a single injection PTH gene expression in normal rats. Very high doses of
[22, 25], a two-day administration [20], or a maximum OCT (0.8 to 5.2 mg/rat) were needed to induce a maxi-
duration of two weeks of treatment [24]. However, in mum decrease of 44% in PTH mRNA [19]. Moreover,
the study of Kubrusly et al, uremic rats given OCT for in our study, animals received supplemental phosphate,
not more than five days developed hypercalcemia [23]. which may have counteracted, at least in part, the sup-
It is also likely that the severity of secondary hyperpara- pressive effect of OCT on PTH secretion.
thyroidism and/or the amount of dietary calcium may Our study reports, for the first time, the long-term
play a role in the development of hypercalcemia. effects of OCT administration on bone histology. By
In our study, long-term OCT administration did not decreasing serum PTH levels, OCT was expected to ab-
result in lowering of serum PTH levels in animals with
rogate the known histological manifestations of excessnormal kidney function during phases 1 and 2. Only a
PTH on bone [49]. Indeed, OCT prevented or decreasedslight and transient decrease was seen when the highest
the abnormal formation of woven bone and fibrosis.dose of OCT was given during phase 1 (0.1 mg/kg three
However, despite the decrease in serum PTH levels,times per week). This is in contrast with the decrease in
OCT treatment was not associated with a commensurateserum PTH levels found in normal rats given OCT for
suppression in bone turnover. These results are in con-7 to 28 days [21]. However, in the latter study, OCT was
trast with the well-established in vivo suppression ofadministered at doses equivalent to 0.25 and 2.5 mg/kg
bone turnover induced by calcitriol given at low or higherdaily. These doses were associated with hypercalcemia
[21]. The results from both studies are in keeping with doses in patients with renal failure [3, 8, 16, 60, 61]. This
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Table 7. Serum parathyroid hormone and serum calcium levels in and growth factors involved in the recruitment of bone
sham-operated (Sham) dogs receiving 22-oxacalcitriol (OCT) or
cells.vehicle (Veh) during Phase 1 before (week 0), and 15 and 60
weeks after beginning of therapy Moreover, in this study, OCT accelerated the rate
of osteoid mineralization (shortened mineralization lagSham 1 Veh Sham 1 Oct
time) in dogs with normal or impaired renal function. A(N 5 10) (N 5 11)
similar phenomenon was observed in X-linked hypo-Serum parathyroid hormone pg/ml
Week 0 36.2 66.4 33.6 63.6 phosphatemic mice in which OCT improved mineraliza-
Week 15 64.5 620.8 17.6 62.6ab tion [33, 66].
Week 60 62.8 613.2 67.4 617.3
In summary, even though long-term administration ofSerum calcium mg/dl
Week 0 9.9 60.2 9.9 60.1 OCT may be associated with episodes of hypercalcemia,
Week 15 9.9 60.2 10.160.2 this analogue is able to improve mineralization and to
Week 60 10.0 60.2 10.3 60.2
prevent the formation of abnormal bone of inferior qual-
Results are given as means 6 sem. ity (woven bone). Most important, it suppresses PTHa Significantly different from Sham 1 Veh, P , 0.05, t-test
b Significant decrease from baseline, P , 0.05, analysis of variance for repeated overactivity without inducing low bone turnover with its
measures potentially negative consequences [67]. The design of
the experiment does not allow direct comparison of the
effects of calcitriol and OCT. However, there is ample
empiric clinical evidence that treatment with calcitrioldiscrepancy between the effects of OCT and calcitriol
on bone turnover could be explained by an overall lesser induces frequent hypercalcemia and may be associated
with a decrease in bone turnover. We have previouslypotency of the analogue or by the fact that in some Nx
dogs, serum PTH levels were elevated. However, in Nx shown that, even at very low doses, calcitriol can prevent
the increase in serum PTH levels in patients with chronicdogs that could be regularly treated during study 1 (Fig.
2A), serum PTH levels were in the normal range for renal failure prior to dialysis [8]. However, this is accom-
panied by a suppression of bone turnover to values belowcanines, proving potency of the drug, whereas bone turn-
over was elevated (twice as much as Sham animals and normal (adynamic bone disease) in some patients. This
has also been observed in children [16]. Prospective clini-similar to Nx control dogs). The differential end-organ
effect of OCT observed in our study is in keeping with cal trials are needed to determine the relative safety and
efficacy of OCT and calcitriol.a short-term study in which OCT treatment had no effect
on bone histology in normal rats, despite a reduction in
serum PTH concentrations [21]. The discrepancy be- ACKNOWLEDGMENTS
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